Browse our anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Antibodies (CDKN2A)
On are 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies from different suppliers available. A total of 0 Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) products are currently listed.
ARF, ARF-INK4a, CDK4I, CDKN2, CMM2, INK4, INK4A, INK4a-ARF, Ink4a/Arf, MLM, MTS-1, MTS1, P14, P14ARF, P16, p16(INK4a), P16-INK4A, p16Cdkn2a, P16INK4, p16INK4a, P19, p19, P19ARF, Pctr1, TP16
list all antibodies Gene Name GeneID UniProt
Anti-Rat CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771 , Q8N726
Anti-Mouse CDKN2A CDKN2A 12578 P51480 , Q64364

Show all synonyms

More Antibodies against Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. The loss of heterozygosity methylation in the promoter region of the CDKN2A gene, occurred only in the rhabdomyosarcomatous cells with increases in both p16 and p14 (show S100A9 Antibodies) expression.

  2. have shown that p16(INK4A) negatively controls leptin (show LEP Antibodies) at the mRNA level through microRNAs 141 and 146b-5p (miR (show MLXIP Antibodies)-141 and miR (show MLXIP Antibodies)-146b-5p), which bind the leptin (show LEP Antibodies) mRNA at a specific sequence in the 3' untranslated region

  3. DEK (show DEK Antibodies) correlates with IL6 (show IL6 Antibodies) expression in HPV16+/p16+ oropharyngeal squamous cell carcinomas (OPSCC).

  4. P16 DNA methylation (show HELLS Antibodies) in in patients with B cell non-Hodgkin lymphoma

  5. Here we present, as far as we are aware, the first case of metastatic microcystic adnexal carcinoma with DNA sequencing results indicating a mutation in TP53 (show TP53 Antibodies) and chromosomal losses in cyclin dependent kinase inhibitor 2A (CDKN2A) and cyclin dependent kinase inhibitor 2B (CDKN2B (show CDKN2B Antibodies)).

  6. MEK (show MAP2K1 Antibodies) activation cooperates with Cdkn2a and Pten (show PTEN Antibodies) inactivation to induce melanoma

  7. SIX homeobox 1 (SIX1 (show SIX1 Antibodies)) regulates cellular senescence by a p16INK4A (p16)-dependent mechanism.

  8. EGF (show EGF Antibodies) induces hair follicle-derived mesenchymal stem cell proliferation through the EGFR (show EGFR Antibodies)/ERK (show EPHB2 Antibodies) and AKT (show AKT1 Antibodies) pathways, but not through STAT-3 (show STAT3 Antibodies). The G1/S transition was stimulated by upregulation of cyclinD1 and inhibition of p16 expression.

  9. results provide evidence for the influence of genetic variants at CDKN2A/B locus with the risk of developing B-AL

  10. Case Report: knee joint malignant tenosynovial giant cell tumor with CDKN2A/B genomic alteration.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. Loss of p16(INK4a) expression is associated with tumorigenesis.

  2. TBK1 (show TBK1 Antibodies) regulates p16 expression and retinal ganglion cell senescence.

  3. median survival of KPIC mice was longer than that of LSL-KrasG12D; Ink4flox/flox; Ptf1/p48 (show PTF1A Antibodies)-Cre mice (KIC) (89 vs 62 days) and shorter than that of KRAS (KrasG12D), TP53 (show TP53 Antibodies) (Trp53R172H/+) and Ptf1/p48 (show PTF1A Antibodies)-Cre (KPC) mice

  4. importance of p19(Arf) for the cellular response to the low-level DNA damage incurred in culture or upon oncogene (show RAB1A Antibodies) expression, providing new insight into how p19(Arf) serves as a tumor suppressor.

  5. p19ARF prevents neoplastic transformation of Trp53 (show TP53 Antibodies)-deficient hepatocytes.

  6. Cdkn2a gene deletion is associated with colorectal carcinomas.

  7. p16 deficiency promotes nonalcoholic steatohepatitis via dysregulation of lipid metabolism and development of hepatic oxidative stress.

  8. Data show that the Wnt (show WNT2 Antibodies)-effector hepatocyte nuclear factor 1-alpha (Tcf1 (show HNF1A Antibodies)) is recruited to and triggers transcription of the Ink4/Arf tumor suppressor locus, such as as p15Ink4b (show CDKN2B Antibodies), p16Ink4a and p19Arf.

  9. deletion of the Cdkn2a gene in p53 (show TP53 Antibodies)(R172H) -induced SCCs promoted a dramatic increase in metastasis rates and a shorter survival in mice that developed these tumours, compared with those observed in mice with tumours in which Cdkn2a was deleted in the presence of a p53 (show TP53 Antibodies) loss-of-function mutation or wild-type p53 (show TP53 Antibodies).

  10. loss of Brca1 (show BRCA1 Antibodies), a tumor suppressor that functions in DNA damage repair, in the mammary epithelium induced senescence with induction of p16 and a decline of stem cell function, which was rescued by p16 loss.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen Profile

Antigen Summary

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Alternative names and synonyms associated with Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A)

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) antibody
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) antibody
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) antibody
  • ARF antibody
  • ARF-INK4a antibody
  • CDK4I antibody
  • CDKN2 antibody
  • CMM2 antibody
  • INK4 antibody
  • INK4A antibody
  • INK4a-ARF antibody
  • Ink4a/Arf antibody
  • MLM antibody
  • MTS-1 antibody
  • MTS1 antibody
  • P14 antibody
  • P14ARF antibody
  • P16 antibody
  • p16(INK4a) antibody
  • P16-INK4A antibody
  • p16Cdkn2a antibody
  • P16INK4 antibody
  • p16INK4a antibody
  • P19 antibody
  • p19 antibody
  • P19ARF antibody
  • Pctr1 antibody
  • TP16 antibody

Protein level used designations for CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Did you look for something else?